AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$CSTL

Oelschlager Kristen M sold $139K of CSTL

Oelschlager Kristen M (Chief Operating Officer) sold 4,152 shares of CASTLE BIOSCIENCES INC (CSTL) at an average of $33.39 ($33.36–$34.02, $0.14M total) across 2 trades on 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Oelschlager Kristen M
Published Sep 3, 2026, 8:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CSTL
Neutral
high confidence
Mentioned
$CSTL
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CSTLNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to affect valuation; serves as routine compliance disclosure.

02

Market read

Minor insider transaction; limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could affect stock more than this sale.

Relevance 3/10Novelty 4/10Timing: transaction dated Sep 1, filing Sep 3

Background

Form 4 filing from Castle Biosciences Inc. (CSTL) reporting a 10b5‑1 sale by its COO.

Company-level read

Ticker impact

$CSTLNeutralHigh confidence
Context

COO Kristen Oelschlager sold 4,152 shares for $138,642.72 on Sep 1, 2026 via a 10b5‑1 plan.

Expected impact

No significant impact; may cause slight short‑term pressure.

Evidence & confidence

Sale size is small relative to float and disclosed via a routine Form 4; market typically discounts such modest disposals.

Market effects

Sector

No broader sector impact; biotech sector unchanged.

Regional

US market only; negligible regional effect.

Global

None

Counterpoint

What could challenge this read

If insider confidence is low, could signal upcoming weakness, but evidence is weak.

Key entities

  • Company
    Castle Biosciences Inc.

    US‑listed biotech firm (ticker CSTL).

  • Executive
    Kristen M. Oelschlager

    Chief Operating Officer of Castle Biosciences.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CSTL insider trading history →

Related articles

SEP 28
$CSTLMedAI 8/10

Castle Biosciences Reports TissueCypher Changed Management In 90% Of NDBE Patients

Castle Biosciences (CSTL) published a study showing its TissueCypher test changed management in 90% of NDBE patients. The test, using AI-derived spatialomics, classified 17% as high risk, leading to escalated management, and 83% as low risk, leading to de-escalated management. The study involved 30 patients at Keck Medical Center of USC and was published in Foregut.

rttnews.com2 min
AUG 8
$CSTLMedAI 8/10

Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript

Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.

fool.com6 min
JUL 30
$CSTLHigh

CASTLE BIOSCIENCES INC (CSTL): Results of Operations and Financial Condition

CASTLE BIOSCIENCES INC (CSTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Castle Biosciences Reports Second Quarter 2026 Results Delivered Q2 2026 revenue of $103.5 million Q2 2026 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 32% over Q2 2025 Raising full-year 2026 revenue guidance to

SEC EDGAR 8-K6 min